Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement in targeted cancer treatment. This innovative antibody-drug conjugate pairs a monoclonal immunoglobulin specifically directed at https://hannahpjc395715.wikiexpression.com/user